Tesamorelin 5 mg

Product Overview

Tesamorelin 5 mg by Axiolabs is supplied as a vial labeled as containing 5 mg of Tesamorelin. Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH), also called growth hormone-releasing factor (GHRF). It acts primarily at the pituitary gland to stimulate endogenous growth hormone secretion and consequently increase circulating insulin-like growth factor-1 (IGF-1).

Tesamorelin differs from recombinant human growth hormone because it does not directly replace GH. Instead, it stimulates the patient's own pituitary GH secretion through the physiological GHRH receptor pathway.

Tesamorelin is an established active pharmaceutical substance. FDA-approved Tesamorelin products include Egrifta SV and the newer Egrifta WR, which are indicated for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Egrifta WR was licensed in the United States in March 2025 and is supplied as an 11.6 mg multidose vial, while Egrifta SV remains available as a 2 mg single-dose vial.

Importantly, FDA labeling states that Tesamorelin is not indicated for general weight-loss management and is considered weight-neutral in its approved HIV-lipodystrophy application.

Approval of specific Egrifta formulations does not establish regulatory approval or therapeutic interchangeability for an independently supplied Axiolabs 5 mg vial. The 5 mg designation should therefore be understood as stated vial content rather than an FDA-approved single dose or treatment schedule.

Product Class

• Growth hormone-releasing hormone (GHRH) analogue
• Growth hormone-releasing factor (GHRF) analogue
• Pituitary growth-hormone secretagogue
• Peptide-based endocrine agent
• GH/IGF-1 axis modulator
• Visceral-adipose-tissue modifying therapy
• Non-androgenic compound
• Non-SARM compound

Mechanism of Action

Tesamorelin is an analogue of endogenous GHRH. It binds to GHRH receptors on pituitary somatotroph cells, stimulating synthesis and pulsatile secretion of endogenous growth hormone.

The resulting increase in GH signaling subsequently raises production of IGF-1, primarily from the liver and other tissues.

This GH/IGF-1 pathway can influence:

• Lipolysis and adipose-tissue metabolism
• Visceral fat distribution
• Protein metabolism
• Lean-body-mass regulation
• Bone metabolism
• Connective-tissue physiology
• Glucose and insulin physiology

Tesamorelin acts upstream of growth hormone. This distinguishes it from recombinant somatropin, which directly supplies exogenous GH.

Because pituitary function remains part of the mechanism, Tesamorelin depends on an intact hypothalamic-pituitary axis. Approved labeling consequently contraindicates its use in patients with disruption of this axis.

Potential Benefits

The best-supported benefit of Tesamorelin is selective reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy.

Potential clinically observed effects include:

• Reduction in visceral adipose tissue
• Reduction in waist circumference
• Improvement in selected body-composition parameters
• Increase in circulating IGF-1
• Potential increase in lean body mass
• Reduction of hepatic fat in selected HIV-associated populations

In adults with abdominal obesity and reduced GH secretion outside the HIV population, a randomized study also found reductions in visceral adipose tissue and improvements in triglycerides and selected cardiovascular-risk markers during Tesamorelin treatment. However, this remains research evidence rather than an approved obesity indication.

Potential benefits must be balanced against endocrine and metabolic risks. Approved labeling identifies elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity reactions, injection-site reactions, and potential neoplasm-related concerns as clinically important issues.

Synergy & Stacking

Tesamorelin acts through the GH/IGF-1 axis and is sometimes discussed alongside other compounds that affect growth-hormone signaling or body composition. These combinations are not validated performance protocols.

• Ipamorelin: A ghrelin/GHS-R1a receptor agonist that stimulates GH through a different pituitary signaling pathway.
• CJC-1295: Another GHRH-related peptide with pharmacology that overlaps more directly with Tesamorelin.
• Growth Hormone: Direct recombinant GH replacement rather than upstream stimulation of endogenous secretion.
• MK-677 / Ibutamoren: Oral ghrelin-receptor agonist that increases endogenous GH and IGF-1.
• Testosterone: Androgen-receptor agonist with a fundamentally different endocrine mechanism.

Combining Tesamorelin with another GHRH analogue, GH secretagogue, or exogenous growth hormone could increase overall GH/IGF-1 exposure and potentially increase risks such as edema, arthralgia, carpal-tunnel symptoms, glucose intolerance, and persistently elevated IGF-1.

There is no established clinical "peptide stack" showing that combining Tesamorelin with CJC-1295, Ipamorelin, MK-677, or growth hormone improves athletic performance or body composition more safely than medically supervised monotherapy.

HRT/TRT Application

Tesamorelin is not Testosterone Replacement Therapy.

It does not:

• Supply Testosterone
• Primarily activate androgen receptors
• Replace androgen deficiency
• Act as a testosterone ester
• Function as a SERM
• Function as an aromatase inhibitor

Tesamorelin instead stimulates the pituitary GH/IGF-1 axis. It therefore belongs to a different endocrine pathway from testosterone replacement.

It should also not be described as conventional growth-hormone replacement. In true GH deficiency, treatment strategies depend on the underlying disorder, and Tesamorelin's approved use is not generalized GH replacement.

Dosing and Use

Axiolabs Tesamorelin is labeled as containing 5 mg per vial. This represents stated vial content only.

Approved Tesamorelin formulations demonstrate why vial strength cannot be converted directly into dosing instructions. Current Egrifta WR contains 11.6 mg per multidose vial and has an approved dosage of 1.28 mg subcutaneously once daily. By contrast, Egrifta SV contains 2 mg per single-dose vial and has an approved dosage of 1.4 mg once daily. FDA specifically states that these formulations are not substitutable because their strengths, preparation, storage, and dosing instructions differ.

Therefore, the 5 mg content of an Axiolabs vial should not be assumed to equal a single dose or to be interchangeable with either approved Egrifta formulation.

No FDA-approved Tesamorelin regimen exists for:

• Bodybuilding
• General fat loss
• Anti-aging
• Muscle gain
• Athletic recovery
• Growth-hormone optimization in healthy individuals

For independently supplied injectable peptide products, clinically relevant quality considerations include molecular identity, peptide purity, sterility, endotoxin levels, concentration accuracy, stability after reconstitution, and appropriate storage.

Female Use

Tesamorelin is not androgenic and is therefore not expected to produce the virilizing effects associated with anabolic-androgenic steroids.

Classical androgenic effects such as voice deepening, clitoral enlargement, facial-hair growth, or androgenic scalp-hair loss are not expected from its GHRH mechanism.

However, women remain susceptible to the endocrine and metabolic effects of elevated GH and IGF-1, including:

• Fluid retention
• Peripheral edema
• Joint discomfort
• Muscle discomfort
• Carpal-tunnel-type symptoms
• Glucose intolerance
• Injection-site reactions

Pregnancy is contraindicated under approved Tesamorelin labeling. Visceral adipose tissue normally increases during pregnancy and modifying this physiological process offers no known benefit while potentially creating fetal risk.

The 5 mg vial strength should not be interpreted as a validated female dose.

Comparative Analysis

Tesamorelin vs CJC-1295

• Tesamorelin: GHRH analogue with an established FDA-approved indication for HIV-associated lipodystrophy in specific branded formulations.
• CJC-1295: Investigational GHRH analogue without an equivalent approved routine therapeutic role.
• Both stimulate GH through the GHRH receptor pathway, but their clinical evidence and regulatory status differ substantially.

Tesamorelin vs Ipamorelin

• Tesamorelin: Activates pituitary GHRH receptors.
• Ipamorelin: Activates the ghrelin/GHS-R1a receptor.
• Both can stimulate endogenous GH, but through different receptor systems.

Tesamorelin vs Growth Hormone

• Tesamorelin: Stimulates endogenous pulsatile GH release from the pituitary.
• Somatropin: Directly supplies recombinant human growth hormone.
• Tesamorelin therefore requires functional pituitary GH-secretory capacity.

Tesamorelin vs MK-677

• Tesamorelin: Injectable GHRH analogue.
• MK-677 / Ibutamoren: Orally active ghrelin-receptor agonist and GH secretagogue.
• Both can increase GH/IGF-1 but have different receptor targets and clinical-development histories.

Tesamorelin vs Semaglutide

• Tesamorelin: GHRH analogue that selectively reduces visceral adipose tissue in its approved HIV-lipodystrophy population.
• Semaglutide: GLP-1 receptor agonist used in approved products for metabolic disease and chronic weight management.
• Tesamorelin is specifically labeled as not being a general weight-loss medicine.

Tesamorelin vs Tirzepatide

• Tesamorelin: Acts through pituitary GHRH receptors and the downstream GH/IGF-1 pathway.
• Tirzepatide: Dual GIP/GLP-1 receptor agonist affecting appetite, glucose regulation, and body weight.
• Their mechanisms and approved clinical indications are fundamentally different.

Conclusion

Tesamorelin 5 mg by Axiolabs is supplied as a vial labeled with 5 mg of Tesamorelin. Tesamorelin is a GHRH analogue that stimulates endogenous growth-hormone release and increases downstream IGF-1 signaling.

The active substance has an established clinical role in FDA-approved Egrifta formulations for reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Current FDA records list Egrifta SV 2 mg and Egrifta WR 11.6 mg as licensed formulations, with Egrifta WR becoming licensed in March 2025.

However, Tesamorelin is not approved as a general weight-loss, bodybuilding, anti-aging, or athletic-performance drug. The regulatory approval and dosing of Egrifta cannot automatically be transferred to an independently manufactured 5 mg vial. The stated 5 mg concentration therefore represents vial content rather than an individualized or regulator-approved dosing recommendation.